0.00Open0.55Pre Close0 Volume12 Open Interest30.00Strike Price0.00Turnover0.00%IV312.84%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma13.45Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet